TICKERNERD
Menu
OFIXOFIXHealthcare · Medical Devices

OFIX Stock Forecast: Orthofix Medical, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$10
0.00% on the day

The 5 Wall Street analysts covering Orthofix Medical, Inc. hold a median 12-month price target of $13 — +29.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$407.7M
Ticker Nerd rank
81 / 100
Median analyst target
$13
Analysts covering
5
Total return, dividends reinvested
1W
−3.2%
1M
−13.9%
YTD
−34.0%
1Y
−31.2%
From 52W high
−38.3%
From 52W low
+11.8%
$9
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OFIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Orthofix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
90
Quality
88
Accruals
74
Revisions
70
Volatility
65
Value
59
Size
57
Momentum
43
Issuance
23

Growth (90): Sales and profits are climbing, and climbing faster than before.

Issuance (23): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OFIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OFIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$8$10$12$14$16Oct 25Jan 26Apr 26Jul 26OFIXHigh $14Median $13Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $12Median $13High $14

The green dot is the last close — the median target sits +29.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Aug 2026Canaccord GenuityMaintainsBuy$18 → $13
6 July 2026Barrington ResearchMaintainsOutperform$15 → $17
6 July 2026Barrington ResearchMaintainsOutperform—
22 May 2026Barrington ResearchMaintainsOutperform—
22 May 2026Canaccord GenuityMaintainsBuy—
22 May 2026StifelMaintainsBuy—
10 Apr 2026Barrington ResearchMaintainsOutperform—
9 Mar 2026StifelMaintainsBuy—
26 Feb 2026Canaccord GenuityMaintainsBuy—
25 Feb 2026Barrington ResearchMaintainsOutperform—
17 Feb 2026Barrington ResearchMaintainsOutperform—
27 Jan 2026TD CowenInitiatesHold—
5 Nov 2025Barrington ResearchMaintainsOutperform—
28 Oct 2025StifelReinstatesBuy$22
23 Oct 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
23 June 2025Barrington ResearchInitiatesOutperform—
6 June 2025JMP SecuritiesReiteratesMarket Perform—
26 Feb 2025Canaccord GenuityMaintainsBuy—
26 Feb 2025Roth MKMReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OFIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

OFIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+36.7%
Analysts raising
1
Analysts cutting
0
Fundamentals

Orthofix Medical, Inc. (OFIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.3×

Cheaper than 89% of US stocks

Price / sales
0.5×

Cheaper than 83% of US stocks

Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
27.0×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
3.8%

Higher than 36% of US stocks

Earnings growth (YoY)
3.8%

Higher than 40% of US stocks

Gross margin
71.0%

Higher than 84% of US stocks

Operating margin
−3.3%

Higher than 29% of US stocks

Net margin
−7.4%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−13.9%

Higher than 34% of US stocks

Return on assets
−2.7%

Higher than 35% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

OFIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
OFIXOrthofix Medical, Inc.$407.7M
81
PACBPacific Biosciences of California, Inc.$407.7M
43
CATXPerspective Therapeutics, Inc.$375.9M
30
MASS908 Devices, Inc.$438.2M
84
SGHTSight Sciences, Inc.$446.1M
86
MOBIMobia Medical, Inc.$351.0M
2
CLPTClearpoint Neuro, Inc.$457.8M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Orthofix Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OFIX news & analysis

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

MarketBeat · 16 Aug 2026neutral

Orthofix Medical executives said the company's updated outlook reflects restored bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.

Why it matters — The revision shows a mix of supportive reimbursement and product-line tailwinds weighed against a weakening U.S. spine distribution channel, which directly bears on Orthofix's forward performance.

Orthofix Medical Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026neutral

Orthofix Medical reported second-quarter results, which management said reflected improving operating trends across several businesses, while weakness among smaller U.S. spine distributors remained a headwind. The company reiterated its focus on commercial productivity, disciplined investment, and profitable growth rather than pursuing revenue growth at any cost.

Why it matters — The call offers watchers an update on Orthofix's operating performance and its strategic emphasis on disciplined, profitable growth amid persistent headwinds in U.S. spine distribution.

Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

A Seeking Alpha article presents the transcript of Orthofix Medical Inc.'s Q2 2026 earnings call. The item reproduces the full discussion from the company's quarterly earnings conference.

Why it matters — OFIX watchers would use the transcript to review management's own commentary on the company's second-quarter performance and outlook.

Bet on 5 Top-Ranked Stocks With Rising P/E

Zacks Investment Research · 5 Aug 2026neutral

A Zacks Investment Research article recommends investing in five top-ranked stocks with increasing P/E ratios as an out-of-the-box approach. Orthofix Medical is not mentioned in the piece.

Why it matters — For a OFIX watcher, the article is only relevant if Orthofix were among the five stocks highlighted, which it is not.

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 5 Aug 2026positive

Orthofix reported second-quarter earnings of $0.07 per share, surpassing the Zacks Consensus Estimate of a $0.03 per share loss. This compares with earnings of $0.13 per share in the same quarter a year ago.

Why it matters — OFIX watchers would note that the company outperformed analyst expectations for the quarter, though the year-over-year comparison shows lower earnings than the prior-year period.

FAQ

Frequently asked questions about OFIX stock

What is the OFIX stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Orthofix Medical, Inc. have a median 12-month price target of $13, with estimates ranging from $12 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OFIX stock a buy right now?

Of the 5 analysts covering Orthofix Medical, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Orthofix Medical, Inc. 81 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OFIX?

As at 22 Aug 2026, Orthofix Medical, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).

Will OFIX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +29.9% from the last close, and Ticker Nerd's factor model ranks Orthofix Medical, Inc. 81 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OFIX stock forecast for 2030?

No analyst covering Orthofix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OFIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $14 over the next 12 months.

How has OFIX stock performed over the past year?

Orthofix Medical, Inc. returned -31.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Orthofix Medical, Inc. do?

Orthofix Medical Inc. is a global medical technology company headquartered in Lewisville, Texas.

What is the latest news on OFIX?

The most recent item we track (MarketBeat, 16 Aug 2026): "Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook". Orthofix Medical executives said the company's updated outlook reflects restored bone growth stimulation reimbursement, improving trends in biologics and limb reconstruction, and an expected European inventory order, partly offset by a steeper-than-anticipated decline among smaller U.S. spine distributors.

Company

About Orthofix Medical, Inc.

Orthofix Medical Inc. is a global medical technology company headquartered in Lewisville, Texas. It specializes in developing and distributing innovative devices and therapies for treating musculoskeletal conditions, operating primarily through two segments: Global Spine and Global Orthopedics. The Global Spine segment provides bone growth stimulation devices to promote fusion in the cervical and lumbar spine, noninvasive treatments for non-spinal fractures, spinal hardware, biologics, and enabling technologies such as the 7D FLASH navigation system. The Global Orthopedics segment focuses on specialized limb reconstruction solutions, including systems for fracture repair, deformity correction, and bone transport like the TrueLok Elevate Transverse Bone Transport System for limb preservation in cases of diabetic ulcers and other deformities. Orthofix Medical Inc. serves healthcare providers, hospitals, and patients across the United States, Europe, Brazil, and other international markets, offering products that support bone healing, spinal fixation, and orthopedic reconstruction procedures.

CEO Mr. Massimo Calafiore · 1,605 employees · United States · https://orthofix.com